NEXUS BIOPHARMA INC: 10-Q filed 2017-10-27

Name: NEXUS BIOPHARMA INC: 10-Q filed 2017-10-27
Creator: NEXUS BIOPHARMA INC
License: https://creativecommons.org/licenses/by/4.0/

What NEXUS BIOPHARMA INC reported in its quarterly report filed 2017-10-27 (fiscal Q1 2018): 19 published measures, 39 facts as tagged in accession 0001213900-17-011006.

This filing

Form: 10-Q (quarterly report)
Filed: 2017-10-27
Fiscal period: fiscal Q1 2018
Accession: 0001213900-17-011006 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; a measure with a published history links to it, and the history shows the latest-filed value per period. All NEXUS BIOPHARMA INC filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2017-05-31	17,900	USD
At 2017-02-28	9,527	USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

Period	Value	Unit	Days
At 2017-05-31	1,867,095	USD
At 2017-02-28	1,463,340	USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Period	Value	Unit
At 2017-05-31	8,427	USD
At 2017-02-28	77	USD
At 2016-05-31	125,809	USD
At 2016-02-29	9,925	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2017-03-01 to 2017-05-31	-390,199	USD	92
2016-03-01 to 2016-05-31	-259,658	USD	92

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit	Days
At 2017-05-31	-3,684,646	USD
At 2017-02-28	-3,294,447	USD

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

Period	Value	Unit	Days
At 2017-05-31	1,508	USD
At 2017-02-28	1,575	USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

Period	Value	Unit	Days
2016-03-01 to 2016-05-31	91,800	USD	92

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2017-05-31	9,927	USD
At 2017-02-28	1,077	USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2017-05-31	1,817,649	USD
At 2017-02-28	1,415,561	USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

Period	Value	Unit	Days
At 2017-05-31	200,000	USD
At 2017-02-28	200,000	USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

Period	Value	Unit	Days
2017-03-01 to 2017-05-31	164,970	USD	92
2016-03-01 to 2016-05-31	255,514	USD	92

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

Period	Value	Unit	Days
2017-03-01 to 2017-05-31	7,525	USD	92
2016-03-01 to 2016-05-31	7,500	USD	92

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2017-05-31	64,309,656	shares
At 2017-02-28	64,309,656	shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

Period	Value	Unit	Days
At 2017-05-31	1,771,141	USD
At 2017-02-28	1,776,324	USD

Total equity including noncontrolling interests

Equity including the portion attributable to noncontrolling interests. It is larger than or equal to parent stockholders equity and is not market capitalization.

Period	Value	Unit	Days
At 2017-05-31	-1,849,195	USD
At 2017-02-28	-1,453,813	USD

Net intangible assets excluding goodwill

Intangible assets other than goodwill after amortization and impairment. Internally developed intangibles are usually not recognized, so this understates what a company relies on.

Period	Value	Unit	Days
At 2017-05-31	6,465	USD
At 2017-02-28	6,875	USD

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2017-03-01 to 2017-05-31	157,445	USD	92
2016-03-01 to 2016-05-31	248,014	USD	92

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

Period	Value	Unit	Days
2017-03-01 to 2017-05-31	477	USD	92
2016-03-01 to 2016-05-31	137	USD	92

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

Period	Value	Unit	Days
2017-03-01 to 2017-05-31	-225,229	USD	92
2016-03-01 to 2016-05-31	-4,144	USD	92

Inspect the source

Entity: NEXUS BIOPHARMA INC / CIK 0001424151
Captured: 2026-09-23 02:49 UTC
SEC response SHA-256: 81b0df49b134712b3ab491313fca6e4fc63ab10b540bae43257eb936c9a8216c

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001424151.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))